Ameritas Investment Partners’s Candel Therapeutics CADL Stock Holding History

Ameritas Investment Partners’s Portfolio CADL Stock Details CADL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59.2K	Buy	5,752 +1,736	+43%	+$13.1K	﹤0.01%	2163
2026 Q1	$19.7K	Hold	4,016	–	–	﹤0.01%	2601
2025 Q4	$22.7K	Hold	4,016	–	–	﹤0.01%	2576
2025 Q3	$20.5K	Hold	4,016	–	–	﹤0.01%	2653
2025 Q2	$20.3K	Buy	4,016 +2,075	+107%	+$10.7K	﹤0.01%	2655
2025 Q1	$11K	Hold	1,941	–	–	﹤0.01%	2790
2024 Q4	$16.8K	Hold	1,941	–	–	﹤0.01%	2700
2024 Q3	$13.5K	Hold	1,941	–	–	﹤0.01%	2825
2024 Q2	$12K	Buy	+1,941	New	+$14.6K	﹤0.01%	2858

Other funds holding CADL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Ameritas Investment Partners's CADL Position: Q2 2026 in Review

Ameritas Investment Partners increased its Candel Therapeutics (CADL) stake by 43% in Q2 2026, buying an estimated $13.1K and bringing the position to 5,752 shares worth $59.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2163.

Ameritas Investment Partners first reported a position in CADL in Q2 2024 and has held it in 9 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

Ameritas Investment Partners held 5,752 shares of Candel Therapeutics worth $59.2K as of Q2 2026.
Ameritas Investment Partners bought 1,736 Candel Therapeutics shares in Q2 2026, an estimated $13.1K.
Candel Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2163 holding.
Ameritas Investment Partners first reported a position in Candel Therapeutics in Q2 2024 and has held it in 9 quarters since.
138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.